EMA Refused: Impulsor (milnacipran) — Pierre Fabre Medicament

View source ↗

Summary

The EMA refused approval for Impulsor (milnacipran) for fibromyalgia, following a decision by Pierre Fabre Medicament.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibromyalgia

Drugs mentioned

• Impulsor (milnacipran)

Snippet

Status: Refused. Therapeutic area: Fibromyalgia. MAH: Pierre Fabre Medicament. Decision date: 26/04/2010